- Q4 2023 Mersana Therapeutics Inc Earnings Call TranscriptFeb 28, 2024$4.85 (+13.58%)Earnings
- Mersana Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Q3 2023 Mersana Therapeutics Inc Earnings Call TranscriptNov 07, 2023$1.34 (-3.60%)Earnings
- Mersana Therapeutics Inc UPLIFT Data Update Call TranscriptJul 27, 2023
- Mersana Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Mersana Therapeutics Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Q1 2023 Mersana Therapeutics Inc Earnings Call TranscriptMay 09, 2023$8 (+7.82%)Earnings
- Q4 2022 Mersana Therapeutics Inc Earnings Call TranscriptFeb 28, 2023$6.06 (+11.60%)Earnings
- Q3 2022 Mersana Therapeutics Inc Earnings Call TranscriptNov 07, 2022$6.64 (-11.94%)Earnings
- Mersana Therapeutics Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2022
- Q2 2022 Mersana Therapeutics Inc Earnings Call TranscriptAug 08, 2022$5.25 (+4.17%)Earnings
- Mersana Therapeutics Inc at Cowen Oncology Innovation Summit: Insights for ASCO & EHA (Virtual) TranscriptJun 02, 2022
- Q1 2022 Mersana Therapeutics Inc Earnings Call TranscriptMay 09, 2022$3.18 (-13.35%)Earnings
- Q4 2021 Mersana Therapeutics Inc Earnings Call TranscriptFeb 28, 2022$4.39 (+7.33%)Earnings
- Mersana Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2022
- Mersana Therapeutics Inc at Stifel Healthcare Conference (Virtual) TranscriptNov 17, 2021
- Q3 2021 Mersana Therapeutics Inc Earnings Call TranscriptNov 09, 2021$9.52 (-0.94%)Earnings
- Mersana Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 15, 2021
- Mersana Therapeutics Inc UpRi Clinical Data Update Call TranscriptSep 10, 2021
- Q2 2021 Mersana Therapeutics Inc Earnings Call TranscriptAug 06, 2021$12.37 (+2.06%)Earnings
- Q1 2021 Mersana Therapeutics Inc Earnings Call TranscriptMay 10, 2021$14.92 (-3.24%)Earnings
- Mersana Therapeutics Inc Selection of the NaPi2b Biomarker Cutoff and Commercial Diagnostic Development Path - Corporate Call TranscriptApr 16, 2021
- Q4 2020 Mersana Therapeutics Inc Earnings Call TranscriptFeb 26, 2021$18.18 (-1.03%)Earnings
- Mersana Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2021
- Mersana Therapeutics, Inc. - Special Call TranscriptJan 05, 2021
- Mersana Therapeutics, Inc. - Special Call TranscriptNov 16, 2020
- Mersana Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 11, 2020
- Q3 2020 Mersana Therapeutics Inc Earnings Call TranscriptNov 09, 2020$22.92 (+2.41%)Earnings
- Mersana Therapeutics, Inc. - Special Call TranscriptSep 17, 2020
- Q2 2020 Mersana Therapeutics Inc Earnings Call TranscriptAug 07, 2020$20.27 (-0.98%)Earnings
- Mersana Therapeutics Inc Annual Shareholders Meeting TranscriptJun 12, 2020
- Mersana Therapeutics, Inc. - Special Call TranscriptMay 27, 2020
- Q1 2020 Mersana Therapeutics Inc Earnings Call TranscriptMay 08, 2020$9.81 (-2.10%)Earnings
- Mersana Therapeutics, Inc. - Special Call TranscriptMar 30, 2020
- Q4 2019 Mersana Therapeutics Inc Earnings Call TranscriptFeb 28, 2020$8.66 (-1.03%)Earnings
- Mersana Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 16, 2020
- Q3 2019 Mersana Therapeutics Inc Earnings Call TranscriptNov 06, 2019$1.98 (+7.03%)Earnings
- Q2 2019 Mersana Therapeutics Inc Earnings Call TranscriptAug 08, 2019$3.16 (+3.95%)Earnings
- Q1 2019 Mersana Therapeutics Inc Earnings Call TranscriptMay 09, 2019$5.91 (+5.54%)Earnings
- Q4 2018 Mersana Therapeutics Inc Earnings Call TranscriptMar 08, 2019$4.52 (+7.11%)Earnings
Mersana Therapeutics, Inc. - Special Call Transcript
Good evening, and welcome to Mersana Therapeutics' conference call to review updated XMT-1536 Phase I Dose Escalation Study Data. (Operator Instructions) I would now like to turn the call over to Sarah Carmody, Executive Director, Investor Relations and Corporate Communications. Please proceed.
Good evening, and welcome to our call. A short while ago, we issued a press release detailing the updated clinical data from our ongoing Phase I dose escalation study of XMT-1536. This release as well as the slides we will present today are available on the Investors and Media section of our website at www.mersana.com.
A replay of today's call will also be made available. After our prepared remarks, we will open the call for Q&A. Before I begin, I'd like to mention that our call will contain forward-looking statements within the meaning of federal securities laws. These are not statements of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)